← Back to all trials
Recruiting
NCT07598708
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Conditions: Narcolepsy Type 1, Narcolepsy Type 2
Sex: All
Ages: 18 Years – 70 Years
Healthy volunteers: No
Phase: PHASE2, PHASE3
Enrollment: 222
Sponsor: Centessa Pharmaceuticals (UK) Limited
Location: Columbia, South Carolina Columbia South Carolina
Summary
Narcolepsy Type 1 (NT1) and Narcolepsy Type 2 (NT2) are rare conditions that make people feel very sleepy during the day (often referred to as excessive daytime sleepiness \[EDS\]). People living with these conditions might find it hard to stay alert and pay attention when they are at school, working, driving, or performing other daily activities.
While all conditions result in feeling sleepy, there are some differences in other common symptoms:
* NT1: People with NT1 often feel very tired during the day and experience cataplexy. Cataplexy is a sudden loss of muscle strength, which can cause someone to collapse or lose control of their muscles for a short time. This is often triggered by strong emotions, such as laughter or surprise. They may also have trouble sleeping well at night.
* NT2: People with NT2 feel sleepy during the day, just like NT1, but they do not have cataplexy.
Orexin is a protein in the brain that helps coordinate a system that plays an important role in helping people to stay awake during the daytime. Cleminorexton is designed to mimic the action of orexin. The purpose of this study is to see how safe and tolerable cleminorexton is in NT1 and NT2 and learn about what the drug does to the body. Another goal of the study is to see if cleminorexton can help people with NT1 and NT2 feel less sleepy and make other symptoms better.
Eligibility Criteria
Key Inclusion Criteria:
* 18-70 years of age
* Body Mass Index (BMI) within the range ≥ 17.0 and ≤ 45 kg/m\^2 (inclusive)
* Meets the diagnostic criteria of Narcolepsy Type 1 (NT1) or Type 2 (NT2) according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD-3-TR) criteria
* Is willing and able to discontinue all medications used for the treatment of narcolepsy
* Is willing and able to adhere to additional protocol requirements
Key Exclusion Criteria:
* Medical disorder other than NT1 or NT2, that is associated with excessive daytime sleepiness (EDS)
* Presence of significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological or psychiatric disease
Source: ClinicalTrials.gov (NCT07598708). StuddyBuddy aggregates publicly available trial information.
